CAPR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Stats
Today's Volume	478 266
Average Volume	290 375
Market Cap	151.84M
EPS	$0 ( 2024-02-29 )
Next earnings date	( $-0.110 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.81
ATR14	$0.0100 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Kelliher Mike	Buy	30 000	Stock Option (Right to Buy)
2024-01-02	Kelliher Mike	Buy	29 250	Stock Option (Right to Buy)
2024-01-02	Kelliher Mike	Buy	4 730	Stock Option (Right to Buy)
2024-01-02	Kelliher Mike	Buy	890	Stock Option (Right to Buy)
2024-01-02	Gotwals Philip J	Buy	29 250	Stock Option (Right to Buy)

INSIDER POWER
82.29
Last 97 transactions
Buy: 2 793 824 \| Sell: 402 761

Volume Correlation

Long: 0.07 (neutral)

Short: 0.80 (strong)

Signal:(55.479) Same movement expected

Capricor Therapeutics Inc Correlation

10 Most Positive Correlations
QNST	0.827
LPTH	0.822
MNDY	0.811
CLMT	0.805

10 Most Negative Correlations
LMST	-0.823
NVEI	-0.82

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Capricor Therapeutics Inc Correlation - Currency/Commodity

0.25
( neutral )

0.19
( neutral )

0.00
( neutral )

0.01
( neutral )

0.00
( neutral )

0.49
( neutral )

Capricor Therapeutics Inc Financials

Annual	2023
Revenue:	$25.18M
Gross Profit:	$24.11M (95.75 %)
EPS:	$-0.830

Q4	2023
Revenue:	$12.09M
Gross Profit:	$11.78M (97.46 %)
EPS:	$-0.0249

Q3	2023
Revenue:	$6.19M
Gross Profit:	$5.91M (95.53 %)
EPS:	$-0.250

Q2	2023
Revenue:	$3.92M
Gross Profit:	$3.67M (93.66 %)
EPS:	$-0.290

Financial Reports:

No articles found.

Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.